Reversible dilated cardiomyopathy related to amphotericin B therapy

J Antimicrob Chemother. 2004 Jan;53(1):115-7. doi: 10.1093/jac/dkg472. Epub 2003 Dec 4.

Abstract

We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis. His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB. It is important to recognize the rare and potentially reversible toxicity of AmB.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Amphotericin B / administration & dosage
  • Amphotericin B / adverse effects*
  • Amphotericin B / therapeutic use
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / adverse effects*
  • Antifungal Agents / therapeutic use
  • Cardiomyopathy, Dilated / chemically induced*
  • Coccidioidomycosis / drug therapy*
  • Drug Combinations
  • Echocardiography
  • Humans
  • Injections, Intravenous
  • Male
  • Phosphatidylcholines / administration & dosage
  • Phosphatidylcholines / adverse effects*
  • Phosphatidylcholines / therapeutic use
  • Phosphatidylglycerols / administration & dosage
  • Phosphatidylglycerols / adverse effects*
  • Phosphatidylglycerols / therapeutic use

Substances

  • Antifungal Agents
  • Drug Combinations
  • Phosphatidylcholines
  • Phosphatidylglycerols
  • liposomal amphotericin B
  • Amphotericin B